Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Cyclophosphamide + Vinorelbine in First Line Metastatic TNBC
NCT06690840Phase 2Recruiting
- Sponsor
- European Institute of Oncology
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, vinorelbine and cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by European Institute of Oncology. Primary endpoint: Overall Response Rate at 30 months. Started Mar 2025; status: recruiting.
02
Drugs
atezolizumabvinorelbinecyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06690840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06690840.